Copal Bone Cement Is More Effective in Preventing Biofilm Formation than Palacos R-G by Ensing, Geert T. et al.
ORIGINAL ARTICLE
Copal Bone Cement Is More Effective in Preventing Bioﬁlm
Formation than Palacos R-G
Geert T. Ensing MD, PhD, Jim R. van Horn MD, PhD,
Henny C. van der Mei PhD, Henk J. Busscher PhD,
Danie ¨lle Neut PhD
Received: 13 May 2007/Accepted: 19 February 2008/Published online: 13 March 2008
  The Author(s) 2008
Abstract Bone cements loaded with combinations of
antibiotics are assumed more effective in preventing
infection than bone cements with gentamicin as a single
drug. Moreover, loading with an additional antibiotic may
increase interconnectivity between antibiotic particles to
enhance release. We hypothesize addition of clindamycin
to a gentamicin-loaded cement yields higher antibiotic
release and causes larger inhibition zones against clinical
isolates grown on agar and stronger bioﬁlm inhibition.
Antibiotic release after 672 hours from Copal bone cement
was more extensive (65% of the clindamycin and 41% of
the gentamicin incorporated) than from Palacos R-G
(4% of the gentamicin incorporated). The higher antibiotic
release from Copal resulted in a stronger and more pro-
longed inhibition of bacterial growth on agar. Bacterial
colony counting and confocal laser scanning microscopy of
bioﬁlms grown on the bone cements suggest antibiotic
release reduced bacterial viability, most notably close to
the cement surface. The gentamicin-sensitive Staphylo-
coccus aureus formed gentamicin-resistant small colony
variants on Palacos R-G and therefore Copal more effec-
tively decreased bioﬁlm formation than Palacos R-G.
Introduction
Several studies report the effectiveness of antibiotic-loaded
bone cement in primary and revision arthroplasties [3, 7, 9,
10, 11]. Gentamicin is the most frequently used antibiotic
for loading bone cement because it has a broad antimi-
crobial spectrum and it can withstand the high temperatures
reached during polymerization of the bone cement.
Although gentamicin-loaded bone cement has been used
for decades, its antibiotic release is not very effective
because maximally 15% of the total amount of antibiotic
incorporated is released [12, 33], and release is poorly
controlled and often conﬁned to a high initial release burst
followed by an extremely low release [6], lingering for
several weeks. Low levels of antibiotic release from bone
cements have been reported years after implantation [31],
but this long-lasting low antibiotic release is not considered
therapeutically effective. More important, release of sub-
inhibitory concentrations with time theoretically can
contribute to the development of gentamicin resistance
among infecting bacteria [21, 28].
Musher reported that nearly 50% of the staphylococci in
prosthesis-related infections are gentamicin-resistant [19].
Occurrence of gentamicin-resistant bacterial strains in
prosthesis-related infections has led to the development of
antibiotic-loaded bone cements in which gentamicin is
combined with a second antibiotic [15, 25, 34]. A combi-
nation of antibiotics is not only expected to broaden the
antimicrobial spectrum of the cement, but also may reduce
the occurrence of antibiotic resistance [18]. Copal (Biomet
Merck, Darmstadt, Germany) is a new commercially
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and possesses a similar polymer matrixas Palacos R-G bone
cement (Schering-Plough, Maarssen, The Netherlands),
which was FDA-approved in 2003. Copal contains twice the
amount of gentamicin as Palacos R-G and has clindamycin
added. One report suggests a combination of gentamicin
with clindamycin would act synergistically and kill greater
than 90% of the bacterial strains involved in common
prosthesis-related infections [13].
We hypothesized addition of clindamycin to gentami-
cin-loaded cement yields higher antibiotic release and
results in larger inhibition zones against clinical isolates
grown on agar, and causes stronger bioﬁlm inhibition.
Materials and Methods
We made bone cement discs of two commercially available
gentamicin-loaded bone cements: Palacos R-G (0.5 g
gentamicin base per batch of cement) and Copal (1 g
gentamicin base and 1 g clindamycin base per batch of
cement). To investigate whether Copal increased antibiotic
release when compared with Palacos R-G, samples of both
bone cements were immersed in buffer and the antibiotic
concentration was measured at different times. Possible
larger inhibition zones by Copal were qualitatively inferred
from growth inhibition on agar plates created by both bone
cements at different intervals. Possible increased bioﬁlm
inhibition of Copal was investigated with bacterial plate
counting and with a confocal laser scanning microscope
after 1 and 7 days of growth on samples of both cements.
Twelve discs from each gentamicin-loaded cement were
grouped into four groups of three discs: one group of three
discs was used for the release studies, one group of discs
was used to study the antibacterial efﬁcacy, one group of
three discs was used for bacterial plate counting to evaluate
the number of living bacteria in bioﬁlms on samples of
both cements, and the last group was used to observe the
bioﬁlms on samples of both cements.
We used commercially available, antibiotic-loaded Copal
bone cement containing 1.62 w/w% gentamicin base and
1.62 w/w% clindamycin base and Palacos R-G containing
0.84 w/w% gentamicin base. Palacos R (Schering-Plough),
containing no antibiotics, was included as a control
(Table 1). We performed mixing and preparation of the
bone cements under sterile conditions according to the
manufacturers’ instructions. Cements were prepared by
mixing the powdered methylmethacrylate with the liquid
monomer in a bowl with a spatula under atmospheric
pressure. We spread the doughy bone cement in a poly-
tetraﬂuoroethylene mold after which the mold was
compressed between two glass plates and covered with
copier overhead ﬁlm (MC 110, Oce ´, The Netherlands) to
facilitate removal after hardening. We manually com-
pressed the glass plates up to the time speciﬁed for ﬁnal
hardening and left them in place for at least 24 hours. This
resulted in cylindrical bone cement samples of 1.2 cm
2
with a diameter of 6 mm and a height of 3 mm. The
average weight of a Copal disc was 129 ± 7 mg and
122 ± 2 mg for a Palacos R-G disc.
We ﬁrst studied antibiotic release of Palacos R-G and
Copal bone cement. To be able to detect a true difference of
600 lg/cm
2 with a power of 90%, assuming a standard
deviation of 5 lg/cm
2 in the Palacos group and 150 lg/cm
2
in the Copal group, we needed three samples in each group.
We immersed three samples of each Palacos R-G and Copal
bone cement in 20 mL phosphate-buffered saline (NaCl
8.76 g/L, K2HPO4 0.87 g/L, KH2PO4 0.68 g/L; pH 7.0) at
37  C. Each of the three samples was put in separate 20-mL
volumes of buffer and at designated times (6, 24, 72, 168,
336, 504, 672 hours), 0.5-mL aliquots were taken and the
gentamicin concentration in these aliquots was measured by
ﬂuorescence polarization immunoassay (AxSYM; Abbott
Laboratories, Abbott Park, IL). We determined the clinda-
mycin concentration as released from Copal bone cement
by high-performance liquid chromatography.
Second, we investigated the direct inhibitory effect on
bacterial growth of Palacos R-G and Copal bone cement
with time. We immersed bone cement samples in separate
20-mL volumes of phosphate-buffered saline and two
samples of each bone cement were removed after 6, 24, 72,
168, 336, 504, and 672 hours. After removal, the samples
were air-dried and pressed ﬁrmly in the center of a Tryp-
tone Soya Broth (TSB; Oxoid, Basingstoke, UK) agar plate
inoculated with a gentamicin-sensitive Staphylococcus
Table 1. Composition of Palacos R-G and Copal bone cement pro-
vided by manufacturers
Components Palacos R-G Copal
Powder 40.8 g 42.85 g








Methylmethacrylate 33.8 g 35.41 g
Benzoyl peroxide 0.2 g 0.32 g
Zirconium dioxide 6.0 g 4.27 g
Chlorophyll 0.008 g *
Liquid
Methylmethacrylate 18.4 g 18.4 g
N,N-dimethyl-
p-toluidine
0.4 g 0.38 g
Chlorophyll 0.005 g *
Hydroquinone

*Chlorophyll copper complex E 141;
amount not quantiﬁed.
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123aureus 7323 (minimum inhibitory concentration [MIC]
gentamicin, 0.75 lg/mL; MIC clindamycin, 0.25 lg/mL)
or a gentamicin-resistant coagulase-negative staphylococ-
cus (CNS) 5277 (MIC gentamicin greater than 256 lg/mL;
MIC clindamycin, 0.032 lg/mL). Both strains were clinical
isolates retrieved from infected joint prostheses and cul-
tured from cryopreservative beads (Protect Technical
Service Consultants Ltd, Heywood, UK) onto blood agar
plates at 37  C in ambient air for 24 hours, after which the
cultures were suspended in NaCl 0.9% to a concentration
of 10
8 bacteria/mL. This suspension was used to inoculate
TSB agar plates. We pressed bone cement samples in the
agar 10 minutes after inoculation, after which the plates
were incubated aerobically at 37  C. We qualitatively
inferred inhibitory effects from the zones of inhibition
around the bone cement samples after 24 hours incubation.
Bacteria in a bioﬁlm have a profoundly reduced sus-
ceptibility to antibiotic treatment and, therefore, an ideal
antibiotic-loaded carrier should not only have effective
bacterial growth inhibition, but also should inhibit bioﬁlm
formation [27]. Therefore, as a ﬁnal experiment, we
explored the inhibitory effects of Palacos R-G and Copal
bone cement on bioﬁlm formation. We took one colony of
each strain from a blood agar plate to inoculate a preculture
in 10 mL TSB, which was grown aerobically at 37  C for
24 hours. Then, 100 lL of this preculture was used to
inoculate 10 mL TSB. We placed a bone cement sample of
Palacos R, Palacos R-G, or Copal bone cement into the
TSB to allow bioﬁlm formation on the cement samples.
Bioﬁlms were evaluated after 1 or 7 days. In the formation
of 7-day bioﬁlms, TSB was refreshed every 2 days.
To determine the number of viable bacteria in the bio-
ﬁlms, we placed bone cement samples in separate test tubes
with 2 mL of NaCl 0.9% solution, vortexed them for
10 seconds, and placed them in an ultrasonic bath for
60 seconds to remove the bioﬁlm. The NaCl solution with
bacteria subsequently was diluted serially and 100 lLo f
these dilutions was plated on TSB agar plates and incu-
bated for 24 hours, after which the number of bacteria was
counted. We performed this experiment three times with
different precultures.
We used confocal laser scanning microscopy (CLSM) to
observe the bioﬁlm architecture because it allows nonde-
structive examination. By moving the sample in the
z-direction, stacks of optical sections can be generated,
which can be used to localize labeled structures in three
dimensions and consequently provide a better understand-
ing of the bioﬁlm structure. To analyze the bioﬁlms with
CLSM, we took one sample of each group out of the TSB
and stained them with 5 lL of LIVE/DEAD Baclight
viability stain (Molecular Probes Europe BV, Leiden, The
Netherlands) containing SYTO 9 dye (ﬂuorescent green)
and propidium iodide (ﬂuorescent red) to differentiate
between living and dead bacteria, respectively [26]. In
addition, we stained bioﬁlms with 5 lL calcoﬂuor white
(0.1 mmol/L; ﬂuorescent blue), a polysaccharide-binding
dye used to visualize the extracellular polymeric substance
(EPS). Confocal images were collected using a Leica
TCS-SP2 CSLM (Leica Microsystems Heidelberg GmbH,
Heidelberg, Germany) with beam path settings for ﬂuorescein
isothiocyanate, tetramethylrhodamine isothiocyanate, and
40-6-diamidino-2-phenylindole labels. We collected a cross
section of the bioﬁlm with a x40 objective, and images
were obtained at approximately 1- to 2-lm intervals down
through the bioﬁlm. The number of images, therefore,
corresponded with the thickness of the bioﬁlm.
To compare antibiotic release and the number of living
bacteria in bioﬁlms on samples of Copal and Palacos R-G
bone cement, we performed pairwise comparisons using
the Student’s t-test for independent samples. The number
of study units was three for all experiments and a 95%
(p\0.05, two-tailed) conﬁdence interval was applied for
signiﬁcance.
Results
Addition of clindamycin to gentamicin-loaded cement
enhances antibiotic release. At all times (Fig. 1), genta-
micin release from Copal was higher (p = 0.002) than
from Palacos R-G. Sixty-ﬁve percent of the clindamycin
and 41% of the gentamicin incorporated in Copal were
released after 672 hours, whereas only 4% of the genta-


































Fig. 1 Cumulative gentamicin and clindamycin concentrations in
20 mL phosphate-buffered saline as a function of time after release
from Palacos R-G (open symbols) and Copal (closed symbols) bone
cement are shown. The triangles denote gentamicin release, whereas
the squares indicate clindamycin release. The error bars denote the
average standard deviation over three experiments performed per
group. Copal increased antibiotic release compared with Palacos R-G.
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123Gentamicin release from Palacos R-G stopped almost
completely after the ﬁrst 24 hours, but antibiotic release
from Copal continued for at least 672 hours.
Qualitative examination showed Copal more strongly
inhibits growth on agar plates at all times when compared
with Palacos R-G (Table 2). Palacos R-G initially was
effective in inhibiting growth of a gentamicin-sensitive S.
aureus, but after 72 hours of elution, we no longer
observed inhibition. In comparison, Copal yielded a
stronger and more prolonged bacterial inhibition for at least
the duration of the experiment (672 hours). Palacos R-G
did not inhibit bacterial growth of the gentamicin-resistant
CNS. In contrast, Copal inhibited growth of the gentami-
cin-resistant CNS at all times after elution.
Addition of clindamycin to gentamicin-loaded cement
had an additional effect on bioﬁlm inhibition as observed
with CLSM and after determination of the number of
viable bacteria in the bioﬁlms. Copal increased inhibition
of 1- (p = 0.031) and 7-day-old (p = 0.044) S. aureus
bioﬁlms as compared with Palacos R and Palacos R-G
(Table 3). Analysis by CLSM of the cross-sectional
buildup of S. aureus bioﬁlms (Fig. 2) indicated thicker
bioﬁlms after 7 days on Palacos R (±100 lm) than on
Palacos R-G (± 90 lm) and Copal (± 20 lm). The bioﬁlm
on Palacos R-G bone cement had a high density of live
bacteria compared with the low density or total absence of
live bacteria on Copal bone cement. Moreover, the dead
bacteria present in the bioﬁlm on Palacos R-G bone cement
were located on the bone cement surface, where the con-
centration of released antibiotic was the highest. For
gentamicin-resistant CNS, the average number of viable
bacteria after Day 1 was lower (p = 0.006) on Palacos R-G
(23 9 10
3 CFU/cm
2) and Copal (35 9 10
3 CFU/cm
2) than
on Palacos R (11 9 10
6 CFU/cm
2) with no difference
between both gentamicin-loaded bone cements. On Day 7,
viable counts on Palacos R (10 9 10
7 CFU/cm
2) and
Palacos R-G (16 9 10
7 CFU/cm
2) had increased (p = 0.008),
whereas the number of bacteria on Copal had decreased
(p = 0.001) to below detection. Analysis by CLSM of the
cross-sectional buildup of CNS bioﬁlms (data not shown)
indicated the bioﬁlms were approximately three- to four-
fold thinner than S. aureus bioﬁlms.
Discussion
Bone cements loaded with combinations of antibiotics are
assumed more effective in preventing infection than bone
cements with gentamicin as a single drug. Moreover,
loading with an additional antibiotic may increase inter-
connectivity between antibiotic particles to enhance
Table 2. Antibacterial efﬁcacy as established using the modiﬁed Kirby-Bauer test*
Time after elution (hours) 0 6 24 72 168 336 504 672
Palacos R-G
Staphylococcus aureus 7323 +±±±--NT NT
Coagulase-negative staphylococcus 5277 ------NT NT
Copal
Staphylococcus aureus 7323 + + +++++++
Coagulase-negative staphylococcus 5277 + + + + + + + + ++++
* Inhibition zones against a gentamicin-sensitive Staphylococcus aureus 7323 and a gentamicin-resistant coagulase-negative staphylococcus
5277 strain for Palacos R-G and Copal bone cement at different times after elution; sensitivity is recorded with modiﬁed Kirby-Bauer test if an
inhibition zone of at least 3 mm is present around the cement sample; therefore, zones with a width 3 mm or less were scored with (-), zones
between 4 and 10 mm were scored with (±), zones between 11 and 20 mm were scored with (+), and zones larger than 21 mm were scored with
(++); modiﬁed Kirby-Bauer test was performed in duplicate; NT = not tested.
Table 3. Number of bacteria (
10log CFU/cm
2) in 1- and 7-day-old Staphylococcus aureus 7323 and Coagulase-negative Staphylococci 5277
Bioﬁlms*
10Log CFU/cm
2 Staphylococcus aureus 7323 Coagulase-negative staphylococcus 5277
Day 1 Day 7 Day 1 Day 7
Palacos R 8.1 ± 0.2 8.0 ± 0.2 7.0 ± 0.3 8.0 ± 0.1
Palacos R-G 7.0
 ± 0.4 8.3
 ± 0.1 4.4 ± 0.3 8.2 ± 0.2
Copal 3.1 ± 0.6 0 ± 0 4.6 ± 0.2 0 ± 0
* Bacterial growth results are averages ± standard deviations from three experiments with separately cultured bacteria and different cement
blocks;
±80% small colony variants; CFU = colony-forming units.
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123release. We hypothesized addition of clindamycin to a
gentamicin-loaded cement yields higher antibiotic release,
and causes larger inhibition zones against clinical isolates
grown on agar and stronger bioﬁlm inhibition.
As a potential limitation of this study, we compared
Copal and Palacos R-G bone cement in 20 mL volumes of
ﬂuid, whereas the surface area of a cement disc exposed
relative to the ﬂuid volume is 0.06 cm
-1. In vivo, the ratio
between cement area and surrounding ﬂuid volume is
approximately 100 times larger [32]. A recent report sug-
gested surface to volume concentration has a strong impact
on the gentamicin concentration that can be achieved and,
consequently, on the antibacterial effect of an antibiotic-
loaded bone cement [8]. Moreover, we established the
antibacterial efﬁcacy of both cements by measuring the
inhibition zones against different bacterial strains. Studies
of antibiotic diffusion through agar media are helpful [1],
but zones of inhibition cannot be directly correlated with
the local and systemic antibiotic concentrations. Finally, to
conﬁrm whether these ﬁndings had any clinical impor-
tance, a prospective, randomized-controlled (multicenter)
study would be required to compare the rates of eradication
of infection between the two bone cements.
The manufacturer of Copal bone cement claims their
bone cement is based on the raw materials of Palacos R-G.
Antibiotic release from bone cement is strongly inﬂuenced
by their concentration, quantity, and structure [2]. The
gentamicin concentration in Copal is twice the amount of
that of Palacos R-G. Penner et al. suggested this might
result in more and larger pores [22] as a result of greater
disturbances of the cement matrix after addition of extra
antibiotics. However, other generally unknown factors also
inﬂuence antibiotic release such as the size of the genta-
micin sulphate particles added. In addition, the polymer-to-
monomer ratio of bone cement greatly affects the antibiotic
release rate; increased polymer-to-monomer ratio leads to
increased release of antibiotic from the cement [4]. The
polymer-to-monomer ratios of Palacos R-G and Copal are
1.82 and 1.92, respectively. A higher ratio can lead are
incomplete polymerization and consequently a more por-
ous cement. Prolonged release of antibiotics from bone
cements is largely inﬂuenced by penetration of dissolution
ﬂuids into the polymer matrix, which requires a certain
porosity of the cement [16, 17, 29]. Although the presence
of more pores in Copal cement seems beneﬁcial to anti-
biotic release, the mechanical strength of this bone cement
is negatively affected by the higher quantities of antibiot-
ics. Yet, the mechanical parameters of Palacos R-G and
Copal fulﬁll ISO Standard 5833, but mechanical testing of
Palacos R-G indicates better mechanical properties [13].
We found Copal inhibited bacterial growth on agar plates
up to 672 hours, whereas with Palacos R-G cement, activity
stopped after 48 hours.Thismay explain why Copalcement
was associated with bioﬁlm reduction to below detectable
limits between Days 1 and 7, whereas Palacos R-G was
associated with bioﬁlm increase during that time. During
formation of 7-day–old bioﬁlms, growth medium was
refreshedevery2 days(tomimic thein vivosituationandto
Fig. 2A–C Confocal laser scanning microscopy images of bioﬁlms
on bone cement discs after LIVE/DEAD Baclight and Calcoﬂuor
staining are shown. The live bacteria are green, dead bacteria are red,
and extracellular polysaccharides are blue. Overlay projections show
the 7-day Staphylococcus aureus bioﬁlms on (A) Palacos R, (B),
Palacos R-G, and (C) Copal bone cement. The projection image
(square image, x–y plane, 375 lm 9 375 lm) includes all the slices
in an image stack. The rectangular micrographs on the sides represent
the x–z plane and y–z optical cross sections through the thickness of
the bioﬁlms (the bottom of each bioﬁlm is indicated B [bone cement]
in each cross section). Bar = 10 lm. Copal reduced bioﬁlm to a level
that no or only a few bacteria were visible on confocal laser scanning
microscopy.
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gentamicin released during the ﬁrst 2 days without contin-
ued release from Palacos R-G cement, whereas antibiotic
release from Copal evidently did continue. Thus, bacteria
abletosurvivetheinitialgentamicinreleasefromPalacosR-
Gsubsequentlyareabletogrowandformabioﬁlm,whereas
the prolonged high release from Copal cement inhibits bac-
terial bioﬁlm formation.
Bacterial colony counting of the gentamicin-sensitive S.
aureus bioﬁlm on Palacos R-G cement discs resulted in two
macroscopically different colonies. Part of the colonies had
a normal size with a distinct hemolytic zone, whereas other
colonies were smaller and showed no signs of hemolysis.
Some authors described this phenomenon for S. aureus and
called these small nonhemolytic colonies ‘‘small colony
variants’’ (SCVs) [5, 30]. Small colony variants of S.
aureus grow slowly and have various other features that are
atypical for S. aureus, including increased resistance to
aminoglycosides (eg, gentamicin) [23, 30]. The connection
of SCVs with persistent and recurrent infections has been
deﬁned during the past decade, especially in patients with
chronic osteomyelitis, cystic ﬁbrosis, and implant-related
infections [5, 24, 30]. In vitro isolation of SCVs is possible
in a kinetic model after exposure to antibiotics [14]. The
number of S. aureus colonies harvested from the Palacos R
and Palacos R-G cement discs after 1 day of growth
showed a bacterial growth reduction of one log-unit,
indicating a rather small reduction resulting from incor-
poration of gentamicin in the cement. This is possibly the
result of the formation of SCVs, because reduced sensi-
tivity to gentamicin is one of the characteristics of SCVs.
Copal was effective in reducing bioﬁlm to a level that
none or only a few bacteria were visible in CLSM. Instead,
an increased and heavy distribution of EPS can be seen
after Day 7 on Copal. Because EPS production impedes the
effect of an antibiotic by protecting the bacteria in the
bioﬁlm, it was suggested this could be considered a sur-
vival mechanism against an antimicrobial attack as
previously described for Pseudomonas aeruginosa [20].
More important, these data suggest effective killing of
adhering bacteria adjacent to the cement surface (Palacos
R-G; Fig. 2B), whereas the outermost layers of the bioﬁlms
remain viable. Systemic antibiotics predominantly attack a
biomaterial-related infection through the outermost layers
of the bioﬁlm, which is usually ineffective as bacteria
continue to grow from the inner layers combined with an
increased production of EPS. This constitutes the main
reason why infected joint replacements nearly always must
be removed to eradicate the infection. Combined use of an
antibiotic-releasing bone cement and systemic antibiotics
thus sandwiches the bioﬁlm between two antimicrobial
attacks with increased chances for resolution of the bioﬁlm,
possibly reducing the risk of revision surgery.
Our data suggest antibiotic release from the bone cement
surface kills adhering bacteria adjacent to the surface with
Copal being more effective in bioﬁlm reduction than
Palacos R-G.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. AltV,BechertT,Steinru ¨ckeP,WagenerM,SeidelP,DingeldeinE,
Domann E, Schnettler R. In vitro testing of antimicrobial
activity of bone cement. Antimicrob Agents Chemother. 2004;48:
4084–4088.
2. Baker AS, Greenham LW. Release of gentamicin from acrylic
bone cement: elution and diffusion studies. J Bone Joint Surg Am.
1988;70:1551–1557.
3. Buchholz HW, Engelbrecht H. U ¨ber die Depotwirkung einiger
AntibioticabeiVermischungmitdemKunstharzPalacos.Chirurg.
1970;41:511–515.
4. Downes S. Methods for improving drug release from
poly(methyl)methacrylate bone cement. Clin Mater. 1991;7:227–
231.
5. Drenkard E, Ausubel FM. Pseudomonas bioﬁlm formation and
antibiotic resistance are linked to phenotypic variation. Nature.
2002;416:740–743.
6. Dunne N, Hill J, McAfee P, Todd K, Kirkpatrick R, Tunney M,
Patrick S. In vitro study of the efﬁcacy of acrylic bone cement
loaded with supplementary amounts of gentamicin: effect on
mechanical properties, antibiotic release, and bioﬁlm formation.
Acta Orthop. 2007;78:774–785.
7. Espehaug B, Engesaeter LB, Vollset SE, Havelin LI, Langeland
N. Antibiotic prophylaxis in total hip arthroplasty: review of
10,905 primary cemented total hip replacements reported to the
Norwegian arthroplasty register, 1987 to 1995. J Bone Joint Surg
Br. 1997;79:590–595.
8. Hendriks JG, Neut D, van Horn JR, van der Mei HC, Busscher
HJ. Bacterial survival in the interfacial gap in gentamicin-loaded
acrylic bone cements. J Bone Joint Surg Br. 2005;87:272–276.
9. Jiranek W. Antibiotic-loaded cement in total hip replacement:
current indications, efﬁcacy, and complications. Orthopedics.
2005;28(8 suppl):s873–877.
10. Josefsson G, Gudmundsson G, Kolmert L, Wijkstrom S. Pro-
phylaxis with systemic antibiotics versus gentamicin bone cement
in total hip arthroplasty: a ﬁve-year survey of 1688 hips. Clin
Orthop Relat Res. 1990;253:173–178.
11. Josefsson G, Kolmert L. Prophylaxis with systematic antibiotics
versus gentamicin bone cement in total hip arthroplasty: a ten-
year survey of 1,688 hips. Clin Orthop Relat Res. 1993;292:210–
214.
12. Kuechle DK, Landon GC, Musher DM, Noble PC. Elution of
vancomycin, daptomycin, and amikacin from acrylic bone
cement. Clin Orthop Relat Res. 1991;264:302–308.
13. Ku ¨hn K-D. Bone Cements. Up-to-date Comparison of Physical
and Chemical Properties of Commercial Materials. 1st ed.
Berlin, Germany: Springer Verlag; 2000:253–258.
14. Langford PR, Anwar H, Gonda I, Brown MR. Outer membrane
proteins of gentamicin induced small colony variants of Pseu-
domonas aeruginosa. FEMS Microbiol Lett. 1989;52:33–36.
15. Mc Gowan JE Jr, Terry PM, Huang TS, Houk CL, Davies J.
Nocosomial infections with gentamicin-resistant Staphylococcus
Volume 466, Number 6, June 2008 Copal vs Palacos R-G Bone Cement 1497
123aureus: plasmid analysis as an epidemiologic tool. J Infect Dis.
1979;140:864–872.
16. McLaren AC, McLaren SG, McLemore R, Vernon BL. Particle
size of ﬁllers affects permeability of polymethylmethacrylate.
Clin Orthop Relat Res. 2007;461:64–67.
17. McLaren AC, McLaren SG, Smeltzer M. Xylitol and glycine
ﬁllers increase permeability of PMMA to enhance elution of
daptomycin. Clin Orthop Relat Res. 2006;451:25–28.
18. Murray PR, Pfaller MA, Rosenthal KS, Kobayashi G. Antibac-
terial agents. In: Murray PR, Pfaller MA, Rosenthal KS,
Kobayashi G, eds. Medical Microbiology. 3rd ed. Philadelphia,
PA: Mosby-Year Book, Inc; 1998:165–168.
19. MusherDM.TheGram-positivecocci:III.Resistancetoantibiotics.
Hosp Pract (Off Ed). 1988;23:105–107, 111–112, 117–118 passim.
20. Neut D, Hendriks JGE, van Horn JR, van der Mei HC, Busscher
HJ. Pseudomonas aeruginosa bioﬁlm formation and slime
excretion on antibiotic-loaded bone cement. Acta Orthop.
2005;76:109–114.
21. NeutD,vandeBeltH,vanHornJR,vanderMeiHC,BusscherHJ.
Residual gentamicin-release from antibiotic-loaded polymethyl-
methacrylate beads after 5 years of implantation. Biomaterials.
2003;24:1829–1831.
22. Penner MJ, Masri BA, Duncan CP. Elution characteristics of
vancomycin and tobramycin combined in acrylic bone-cement.
J Arthroplasty. 1996;11:939–944.
23. Proctor RA, Peters G. Small colony variants in staphylococcal
infections: diagnostic and therapeutic implications. Clin Infect
Dis. 1998;27:419–422.
24. Sendi P, Rohrbach M, Graber P, Frei R, Ochsner PE, Zimmerli
W. Staphylococcus aureus small colony variants in prosthetic
joint infection. Clin Infect Dis. 2006;43:961–967.
25. Speller DC, Raghunath D, Stephens M, Viant AC, Reeves DS,
Wilkinson PJ, Broughall JM, Holt HA. Epidemic infection by a
gentamicin-resistant Staphylococcus aureus in three hospitals.
Lancet. 1976;1:464–466.
26. Stewart PS, Murga R, Srinivasan R, Debeer D. Bioﬁlm structural
heterogeneity visualized by 3 microscopic methods. Water
Research. 1995;29:2006–2009.
27. Tunney MM, Dunne N, Einarsson G, McDowell A, Kerr A,
Patrick S. Bioﬁlm formation by bacteria isolated from
retrieved failed prosthetic hip implants in an in vitro model
of hip arthroplasty antibiotic prophylaxis. J Orthop Res. 2007;
25:2–10.
28. van de Belt H, Neut D, van Horn JR, van der Mei HC,
Schenk W, Busscher HJ. …or not to treat? Nat Med. 1999;5:358–
359.
29. van de Belt H, Neut D, Uges DR, Schenk W, van Horn JR, van
der Mei HC, Busscher HJ. Surface roughness, porosity and
wettability of gentamicin-loaded bone cements and their antibi-
otic release. Biomaterials. 2000;21:1981–1987.
30. von Eiff C, Bettin D, Proctor RA, Rolauffs B, Lindner N,
Winkelmann W, Peters G. Recovery of small colony variants of
Staphylococcus aureus following gentamicin bead placement for
osteomyelitis. Clin Infect Dis. 1997;25:1250–1251.
31. Wahlig H, Dingeldein E. Antibiotics and bone cements: experi-
mental and clinical long-term observations. Acta Orthop Scand.
1980;51:49–56.
32. Wang JS, Franzen H, Lidgren L. Interface gap after implantation
of a cemented femoral stem in pigs. Acta Orthop Scand.
1999;70:234–239.
33. Wroblewski BM, Esser M, Srigley DW. Release of gentamicin
from bone cement: an ex-vivo study. Acta Orthop Scand.
1986;57:413–414.
34. Wyatt TD, Ferguson WP, Wilson TS, McCormick E. Gentamicin
resistant Staphylococcus aureus associated with the use of topical
gentamicin. J Antimicrob Chemother. 1977;3:213–217.
1498 Ensing et al. Clinical Orthopaedics and Related Research
123